CN110191718A - 一种预防和治疗组织器官纤维化的方法 - Google Patents

一种预防和治疗组织器官纤维化的方法 Download PDF

Info

Publication number
CN110191718A
CN110191718A CN201780078169.0A CN201780078169A CN110191718A CN 110191718 A CN110191718 A CN 110191718A CN 201780078169 A CN201780078169 A CN 201780078169A CN 110191718 A CN110191718 A CN 110191718A
Authority
CN
China
Prior art keywords
plasminogen
fibrosis
histoorgan
caused
collagen deposition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078169.0A
Other languages
English (en)
Inventor
李季男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Talengen Institute of Life Sciences Co Ltd
Original Assignee
Talengen Institute of Life Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Institute of Life Sciences Co Ltd filed Critical Talengen Institute of Life Sciences Co Ltd
Publication of CN110191718A publication Critical patent/CN110191718A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

本发明涉及一种预防和治疗组织器官纤维化的方法，包括给药受试者有效量的纤溶酶原。

Description

PCT国内申请，说明书已公开。

Claims (44)

  1. PCT国内申请，权利要求书已公开。
CN201780078169.0A 2016-12-15 2017-06-19 一种预防和治疗组织器官纤维化的方法 Pending CN110191718A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/110174 2016-12-15
CN2016110174 2016-12-15
PCT/CN2017/089058 WO2018107698A1 (zh) 2016-12-15 2017-06-19 一种预防和治疗组织器官纤维化的方法

Publications (1)

Publication Number Publication Date
CN110191718A true CN110191718A (zh) 2019-08-30

Family

ID=62557850

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201780078123.9A Pending CN110114080A (zh) 2016-12-15 2017-06-19 一种预防和治疗皮肤纤维化的方法
CN201780078132.8A Pending CN110121358A (zh) 2016-12-15 2017-06-19 一种预防和治疗肺纤维化的方法
CN201780078169.0A Pending CN110191718A (zh) 2016-12-15 2017-06-19 一种预防和治疗组织器官纤维化的方法
CN201780078166.7A Pending CN110139668A (zh) 2016-12-15 2017-06-19 一种预防和治疗肝纤维化的方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201780078123.9A Pending CN110114080A (zh) 2016-12-15 2017-06-19 一种预防和治疗皮肤纤维化的方法
CN201780078132.8A Pending CN110121358A (zh) 2016-12-15 2017-06-19 一种预防和治疗肺纤维化的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780078166.7A Pending CN110139668A (zh) 2016-12-15 2017-06-19 一种预防和治疗肝纤维化的方法

Country Status (7)

Country Link
US (4) US11219669B2 (zh)
EP (4) EP3556395A4 (zh)
JP (4) JP7313058B2 (zh)
CN (4) CN110114080A (zh)
CA (4) CA3046669A1 (zh)
TW (6) TWI734798B (zh)
WO (5) WO2018107698A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI734798B (zh) 2016-12-15 2021-08-01 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療肺纖維化的方法
CN111344004A (zh) 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物
TW201904990A (zh) * 2017-06-23 2019-02-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
JP2023521530A (ja) * 2020-02-11 2023-05-25 タレンゲン インターナショナル リミテッド ウイルス性肺炎を治療する方法及び薬剤
WO2023008283A1 (ja) 2021-07-30 2023-02-02 花王株式会社 パンツ型吸収性物品
CN114984032B (zh) * 2022-06-27 2023-07-07 四川大学 Dna四面体框架核酸-绿原酸复合物及其在制备治疗肝纤维化的药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1768138A (zh) * 2002-02-06 2006-05-03 N-酶生物技术有限公司 在微生物中生产重组蛋白质的方法
CN105705520A (zh) * 2013-08-13 2016-06-22 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
CN106029884A (zh) * 2014-02-21 2016-10-12 安斯泰来制药株式会社 新型抗人pai-1抗体

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
GB8721951D0 (en) * 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
AU724077B2 (en) 1996-05-03 2000-09-14 Abbvie Inc. Novel antiangiogenic peptides, polypeptides encoding same and methods for inhibiting angiogenesis
EP1001985A1 (en) 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
WO2000010506A2 (en) 1998-08-20 2000-03-02 University Of Vermont And State Agriculture College Angiogenesis inhibitors and uses thereof
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
WO2002040510A2 (en) 2000-11-02 2002-05-23 Bristol-Myers Squibb Company Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
MXPA00011713A (es) 2000-11-28 2002-05-31 Tgt Lab S A De C V Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050124036A1 (en) 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
EP1509236A4 (en) 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
DE60306547T2 (de) 2002-12-10 2007-06-28 Wyeth Substituierte 3-alkyl- und 3-arylalkyl-1h-indol-1-yl-essigsäure-derivate als plasminogen-aktivator
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CA2577782A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
DK2056864T3 (en) * 2006-08-28 2014-03-10 Omnio Healer Ab CANDIDATES AGAINST INFECTION
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
EP2220221B1 (en) 2007-11-29 2014-12-31 Grifols Therapeutics Inc. Recombinantly modified plasmin
WO2009111625A2 (en) * 2008-03-05 2009-09-11 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
RU2564131C2 (ru) * 2009-07-10 2015-09-27 ТромбоДженикс НВ Варианты плазминогена и плазмина
CN101628113B (zh) 2009-08-18 2012-01-04 南京农业大学 蚯蚓纤溶酶抗肝纤维化的应用
JP2013510321A (ja) 2009-11-07 2013-03-21 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
BR112013017172A2 (pt) * 2011-01-05 2016-10-11 Thrombogenics Nv variantes de plasminogênio e plasmina
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
EP2822654B1 (en) 2012-03-09 2019-08-28 Vascular Biosciences Orally active, cell-penetrating homing peptide and methods of using same
KR101467109B1 (ko) 2013-07-10 2014-12-01 영남대학교 산학협력단 Ｂｉｘ02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물
TW201722994A (zh) 2013-08-13 2017-07-01 賽諾菲公司 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US20160199466A1 (en) * 2013-08-20 2016-07-14 Trustees Of Dartmouth College Methods For Treating Tissue Fibrosis
MX2017008189A (es) 2014-12-19 2018-03-23 Prometic Bio Therapeutics Inc Composicion farmceutica que comprende plasminogeno y usos de este.
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
CN106890324A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病肾病的方法
WO2017101866A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
CN106890320A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
CA3008466C (en) 2015-12-18 2023-06-20 Talengen International Limited Method for preventing or treating radiation and chemical damage
CA3008186A1 (en) 2015-12-18 2017-06-22 Talengen International Limited Novel method for preventing and treating angiocardiopathy
CN106890318A (zh) 2015-12-18 2017-06-27 深圳瑞健生命科学研究院有限公司 一种预防和治疗糖尿病性心脏病的新方法
US11400142B2 (en) 2015-12-18 2022-08-02 Talengen International Limited Treatment of diabetic nerve injury comprising administering plasminogen
WO2018107707A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种改善心脏病变的方法
WO2018108161A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肥胖症的方法和药物
EP3556386A4 (en) * 2016-12-15 2020-07-08 Talengen International Limited METHOD FOR PREVENTING AND TREATING MEDICINAL-INDUCED KIDNEY LESION
TWI734798B (zh) 2016-12-15 2021-08-01 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療肺纖維化的方法
US11311607B2 (en) 2016-12-15 2022-04-26 Talengen International Limited Method for making glucagon and insulin restore normal balance
CN110167583A (zh) * 2016-12-15 2019-08-23 泰伦基国际有限公司 一种治疗冠状动脉粥样硬化及其并发症的方法
CN111344004A (zh) * 2017-06-19 2020-06-26 泰伦基国际有限公司 一种调控glp-1/glp-1r 的方法和药物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1768138A (zh) * 2002-02-06 2006-05-03 N-酶生物技术有限公司 在微生物中生产重组蛋白质的方法
CN105705520A (zh) * 2013-08-13 2016-06-22 赛诺菲 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途
US20160200831A1 (en) * 2013-08-13 2016-07-14 Sanofi Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof
CN106029884A (zh) * 2014-02-21 2016-10-12 安斯泰来制药株式会社 新型抗人pai-1抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BEIER,J.I等: "Alcoholic liver disease and the potential role of plasminogen activator inhibitor-I and fibrin metabolism", 《EXPERIMENTAL BIOLOGY AND MEDICINE》 *
JOHN F. POHL等: "Plasminogen Deficiency Leads to Impaired Lobular Reorganization and Matrix Accumulation after Chronic Liver Injury", 《AMERICAN JOURNAL OF PATHOLOGY》 *

Also Published As

Publication number Publication date
WO2018107696A1 (zh) 2018-06-21
EP3556382A4 (en) 2020-12-09
EP3556395A4 (en) 2020-07-22
EP3556389A1 (en) 2019-10-23
US11071772B2 (en) 2021-07-27
EP3556380A4 (en) 2020-05-13
TW201822790A (zh) 2018-07-01
WO2018107697A1 (zh) 2018-06-21
CA3046671A1 (en) 2018-06-21
TW201822789A (zh) 2018-07-01
US20190314468A1 (en) 2019-10-17
EP3556380A1 (en) 2019-10-23
US11219669B2 (en) 2022-01-11
JP2020511413A (ja) 2020-04-16
JP2020512288A (ja) 2020-04-23
TWI734798B (zh) 2021-08-01
EP3556382A1 (en) 2019-10-23
CN110121358A (zh) 2019-08-13
CA3046666A1 (en) 2018-06-21
WO2018107693A1 (zh) 2018-06-21
CA3046669A1 (en) 2018-06-21
US20190314467A1 (en) 2019-10-17
JP2020502132A (ja) 2020-01-23
TWI657823B (zh) 2019-05-01
TWI670075B (zh) 2019-09-01
CA3047174A1 (en) 2018-06-21
US20190314466A1 (en) 2019-10-17
CN110139668A (zh) 2019-08-16
TWI752044B (zh) 2022-01-11
EP3556395A1 (en) 2019-10-23
US20190365872A1 (en) 2019-12-05
JP7213553B2 (ja) 2023-01-27
TW201822796A (zh) 2018-07-01
WO2018107694A1 (zh) 2018-06-21
TW201822783A (zh) 2018-07-01
TW201822795A (zh) 2018-07-01
CA3046671C (en) 2023-08-08
CN110114080A (zh) 2019-08-09
TW202123955A (zh) 2021-07-01
EP3556389A4 (en) 2020-07-15
WO2018107698A1 (zh) 2018-06-21
JP7313058B2 (ja) 2023-07-24
JP2020502133A (ja) 2020-01-23
US11154595B2 (en) 2021-10-26
JP7213552B2 (ja) 2023-01-27

Similar Documents

Publication Publication Date Title
TWI752044B (zh) 一種預防和治療組織器官纖維化的方法
CN110167583A (zh) 一种治疗冠状动脉粥样硬化及其并发症的方法
WO2018107695A1 (zh) 一种预防和治疗肾纤维化的方法
CN108210910A (zh) 预防和治疗系统性硬化症的药物及其用途
CN108463236A (zh) 一种预防或治疗放射性和化学性损伤的方法
CN108210893A (zh) 预防和治疗肾纤维化的药物及其用途
CN106890318A (zh) 一种预防和治疗糖尿病性心脏病的新方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination